Today we announced a conference call and webcast to review clinical data from the ongoing Ph 1b trial of enozertinib in 1L NSCLC patients w/ EGFR atypical mutations in conjunction with #ESMO2026 on Fri, Oct 23, 2026, at 8:00 a.m. ET. Learn more: bit.ly/4BdPZFl

We announced an agreement w/ @CR_UK to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy. @CR_UK will lead CTA-enabling studies and Ph 1/2 development, with ORIC® retaining an exclusive option to reacquire rights following Ph 1/2 data. bit.ly/47MHlzT

ORIC’s Exec. Dir. of Translational Medicine, Anneleen Daemen, will present a poster highlighting our experimental therapy rinzimetostat to potentially treat mCRPC at the Prostate Cancer Foundation 33rd Annual Scientific Retreat on Fri, Oct 2, 2026. bit.ly/4686Ef8

ORIC’s VP, Head of Biology, Melissa R Junttila, Ph.D., will present ORIC’s approach to PRC2 inhibition to treat cancer at the HADCC Symposium – Metabolic Rewriting in Cancer and Degenerative Diseases on Mon, Sept 28, 2026. Learn more: bit.ly/3UwX42U

On #WorldCancerResearchDay, we celebrate the scientists, clinicians, patients & advocates advancing cancer research. At ORIC®, we’re working to Overcome Resistance In Cancer by advancing therapies designed to expand what’s possible for patients. #CancerResearch #Oncology

Work hard. Celebrate together. The ORIC® team enjoyed summer outings to connect, recharge and celebrate the people behind our mission. We're proud of a culture that values collaboration, innovation and having fun along the way. #WorkHardPlayHard

This #HispanicHeritageMonth, we celebrate the cultures, contributions and achievements of Hispanic and Latino communities. Diverse perspectives strengthen collaboration, inspire new ways of thinking and help drive the innovation needed to advance science for patients.

$ORIC President & CEO, @JacobChackoMD and CFO @Dom_Piscitelli will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, at 10:00 a.m. ET. Listen to the live or archived discussion here: bit.ly/3VxP4tj

$ORIC President & CEO, @JacobChackoMD and CFO @Dom_Piscitelli will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on September 10, 2026, at 1:35 p.m. ET. Listen to the live or archived discussion here: bit.ly/3VxP4tj

$ORIC President & CEO, @JacobChackoMD and CFO @Dom_Piscitelli will participate in a fireside chat at the @WellsFargo 21st Annual Healthcare Conference on September 9, 2026, at 2:15 p.m. ET. Listen to the live or archived discussion here: bit.ly/3VxP4tj

This #ProstateCancerAwarenessMonth, we stand with patients, families & the prostate cancer community. Our recent initiation of the Himalayas-1 Phase 3 study reinforces our commitment to advancing new treatment options for patients with prostate cancer.

On #WomensEqualityDay, we celebrate the women whose leadership, innovation and dedication shape the future of science & healthcare. We're proud to recognize the women scientists, clinicians, patients, caregivers & advocates helping advance progress toward new cancer therapies.

VP, Head of Biology Melissa Junttila, Ph.D., will highlight data supporting the potential of PRC2 inhibition to restore sensitivity to androgen receptor blockade in mCRPC at the @CSHL: Mechanisms & Models of Cancer meeting Aug 18-22, 2026. Learn more: bit.ly/4hAMYr6

We continue to advance our mission to overcome resistance in cancer: Initiated Himalayas-1 global Ph 3 study in mCRPC Entered into clinical trial collaboration & supply agreement w/ Bayer We anticipate multiple program updates across programs in 2H 2026. bit.ly/4w6EHyP

On #WorldLungCancerDay, we recognize the strength of patients, families, caregivers and advocates, and the researchers working to advance new treatment options. We're advancing development of enozertinib, our brain-penetrant EGFR inhibitor for the potential treatment of #NSCLC.

$ORIC President & CEO, @JacobChackoMD and CFO @Dom_Piscitelli will be available for investor one-on-one meetings at the BTIG Virtual Biotechnology Conference on July 29, 2026. If you're participating, we welcome the opportunity to connect.

Excited to initiate the Himalayas-1 global Ph 3 trial evaluating rinzimetostat in combination w/ NUBEQA® (darolutamide) in patients w/ mCRPC previously treated w/ abiraterone, supported by a clinical trial collaboration & supply agreement w/ Bayer. bit.ly/4b0bLkl

Happy Fourth of July! As we commemorate America's 250th anniversary, we celebrate the innovation and determination that drive progress. Wishing our employees, collaborators, patients, and communities a safe and happy Independence Day.

Making a difference extends beyond the lab. Our team recently volunteered with Ronald McDonald House and a local food bank, supporting families and helping address food insecurity in our community. We're proud to give back and help strengthen the communities we serve. #GivingBack

This #Juneteenth, we honor the resilience, history, and contributions of Black Americans whose impact has helped shape communities, culture, science, and innovation. We recognize the importance of diversity in driving innovation and progress. #DiversityInSTEM